The pending sale of a major American gene-mapping company to a Chinese firm is sparking yet another dust-up over what sensitive industries the rising Asian power ought to be allowed to dominate in the United States.
A key question — as it has been with Chinese involvement in aviation, cloud computing and telecom hardware — is whether there are national security concerns attached to allowing a company largely funded by the Chinese government to have access to human DNA being decoded for doctors, researchers and pharmaceutical companies.
View the original article here: Concerns arise in Chinese bid for genomics firm
